Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

[Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)].

Rodríguez-Galán MA, Pérez-Vilar S, Díez-Domingo J, Tuells J, Gomar-Fayos J, Morales-Olivas F, Pastor-Villalba E.

An Pediatr (Barc). 2014 Nov;81(5):303-9. doi: 10.1016/j.anpedi.2013.11.031. Epub 2014 Feb 26. Spanish.

2.

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J.

JAMA. 2009 Aug 19;302(7):750-7. doi: 10.1001/jama.2009.1201.

PMID:
19690307
3.

The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.

Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.

Hum Vaccin Immunother. 2015;11(3):732-8. doi: 10.1080/21645515.2015.1011570.

4.

Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013.

Šubelj M, Učakar V, Kraigher A, Klavs I.

Euro Surveill. 2016;21(14). doi: 10.2807/1560-7917.ES.2016.21.14.30187.

5.

[Post-licensure passive safety surveillance of rotavirus vaccines: reporting sensitivity for intussusception].

Pérez-Vilar S, Díez-Domingo J, Gomar-Fayos J, Pastor-Villalba E, Sastre-Cantón M, Puig-Barberà J.

An Pediatr (Barc). 2014 Aug;81(2):77-85. doi: 10.1016/j.anpedi.2013.10.027. Epub 2013 Nov 17. Spanish.

6.

Suspected side effects to the quadrivalent human papilloma vaccine.

Brinth L, Theibel AC, Pors K, Mehlsen J.

Dan Med J. 2015 Apr;62(4):A5064.

PMID:
25872549
7.

Syncope and seizures following human papillomavirus vaccination: a retrospective case series.

Crawford NW, Clothier HJ, Elia S, Lazzaro T, Royle J, Buttery JP.

Med J Aust. 2011 Jan 3;194(1):16-8.

PMID:
21449862
8.

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States.

Gee J, Weinbaum C, Sukumaran L, Markowitz LE.

Hum Vaccin Immunother. 2016 Jun 2;12(6):1406-17. doi: 10.1080/21645515.2016.1168952. Epub 2016 Mar 30.

9.

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults.

Moreira ED Jr, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H, Hillman RJ, Ferris D, Coutlee F, Vardas E, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI.

Hum Vaccin. 2011 Jul;7(7):768-75. doi: 10.4161/hv.7.7.15579. Epub 2011 Jul 1.

10.

[Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009-2010 and 2010-2011. Valencian community, Spain].

Alguacil Ramos AM, Lluch Rodrigo JA, Portero Alonso A, Martín Ivorra R, Pastor Villalba E.

Rev Esp Salud Publica. 2012 May-Jun;86(3):241-51. Spanish.

11.

Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.

Luxembourg A, Bautista O, Moeller E, Ritter M, Chen J.

Contemp Clin Trials. 2015 May;42:18-25. doi: 10.1016/j.cct.2015.02.009. Epub 2015 Mar 3.

PMID:
25749310
12.

Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®.

Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN.

Drug Saf. 2017 Jan;40(1):81-90. doi: 10.1007/s40264-016-0456-3.

13.

Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy.

Forinash AB, Yancey AM, Pitlick JM, Myles TD.

Ann Pharmacother. 2011 Feb;45(2):258-62. doi: 10.1345/aph.1P396. Review.

PMID:
21285408
14.

An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.

Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, Lievano F, Velicer C, Drury R, Kuter BJ.

Pediatr Infect Dis J. 2015 Sep;34(9):983-91. doi: 10.1097/INF.0000000000000793. Review.

PMID:
26107345
15.

[News items on human papillomavirus and its vaccine in the Valencian press (2006-2011)].

Tuells J, Duro Torrijos JL, Chilet Rosell E, Pastor Villalba E, Portero Alonso A, Navarro Ortiz C, Galiana de la Villa EM.

Gac Sanit. 2013 Jul-Aug;27(4):374-7. doi: 10.1016/j.gaceta.2012.12.014. Epub 2013 Feb 15. Spanish.

16.

[Suspected adverse events to measles, mumps and rubella vaccine reported to the Community of Valencia Pharmacovigilance Centre].

Pérez-Vilar S, Gutiérrez-Gimeno MV, Rodríguez-Galán MA, Díez-Domingo J, Puig-Barberà J, Gomar-Fayos J, Alguacil-Ramos AM.

An Pediatr (Barc). 2013 May;78(5):297-302. doi: 10.1016/j.anpedi.2012.07.013. Epub 2012 Sep 14. Spanish.

17.

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.

Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M.

Pediatr Infect Dis J. 2015 Sep;34(9):992-8. doi: 10.1097/INF.0000000000000773.

PMID:
26090572
18.

Disease-specific adverse events following nonlive vaccines: a paradoxical placebo effect or a nocebo phenomenon?

Okaïs C, Gay C, Seon F, Buchaille L, Chary E, Soubeyrand B.

Vaccine. 2011 Aug 26;29(37):6321-6. doi: 10.1016/j.vaccine.2011.05.045. Epub 2011 May 31.

PMID:
21627976
19.

Syncope after vaccination--United States, January 2005-July 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 May 2;57(17):457-60.

20.

Introduction of a National HPV vaccination program into Bhutan.

Dorji T, Tshomo U, Phuntsho S, Tamang TD, Tshokey T, Baussano I, Franceschi S, Clifford G.

Vaccine. 2015 Jul 17;33(31):3726-30. doi: 10.1016/j.vaccine.2015.05.078. Epub 2015 Jun 6.

PMID:
26057136

Supplemental Content

Support Center